Investor Notes - Phillip Securities (HK) Ltd

30 Apr, 2019 (Tuesday)

SH PHARMA(2607)
Analysis：
Shanghai Pharmaceuticals is a large-scale pharmaceutical group listed in Shanghai and Hong Kong markets. The group principally engages in pharmaceutical manufacturing, distribution and retail, which is one of the few pharmaceutical listed companies in China with leading positions both in pharmaceutical products and distribution markets. In the first quarter of 2019, the Group's operating revenue exceeded expectations with a YoY increase of 26.4% to RMB 46 billion, and net profit increased by 10.4% on a YoY basis to RMB 1.126 billion. Revenue from pharmaceutical commerce was RMB 39.81 billion (a YoY increase of 26.7%) and revenue from pharmaceutical manufacturing was RMB 6.196 billion (a YoY increase of 24.9%). Net profit from pharmaceutical commerce increased by 13.9% to RMB 510 million and net profit from pharmaceutical manufacturing increased by 21.4% to RMB 513 million (R&D expenses excluded). The integrated gross profit margin was 14.05%, representing an increase of 0.19% compared with the average for 2018. The net operating cash inflows reached RMB154 million, representing a YoY increase of 60.59%. Advantages: The Group continued to push forward consistency evaluation and R&D innovation projects, the R&D expenses in the first quarter was RMB 271 million, representing a YoY growth of 26.7%. The Group has become China's largest distributor of imported drugs, and with China joining the International Council for Harmonization, the Group is expected to continue benefiting from the accelerated approval of abroad new drugs. The Group received the Drug GMP Certificate issued by the Shanghai Medical Products Administration for its Recombinant Human Type-5 Adenovirus (Injection), named Oncorine, the first oncolytic virus product developed in China. The next step will be expanding production to meet market and clinical research demands, and the Group is expected to have considerable sales in the future.
Strategy：
Buy-in Price: $16.24, Target Price: $22.53, Cut Loss Price: $14.77

Ricoh Co., Ltd. ( 7752.JT )
Established in 1936 from a separation of a photosensitive paper department promoting the physics and chemistry industry which carried out the industrialization of invention and design at RIKEN. Deals with office printing, office services, commercial printing, industrial printing and thermal, etc. For 3Q (Apr-Dec) results of FY2019/3 announced on 7/2, net sales increased by 1.8% to 1.4894 trillion yen compared to the same period the previous year, operating income increased by 64.3% to 79.179 billion yen, and net income increased by 2.9 times to 50.633 billion yen. In addition to continued profit expansion in office services, the introduction of new products has led commercial printing to turn towards an increase in profit. Due to the skyrocketing raw material costs for thermal, there has been an increase in revenue but a decrease in profit. For its full year plan, net sales is expected to decrease by 1.1% to 2.4 trillion yen compared to the previous year, and with operating income at 85 billion yen and net income at 60 billion yen, both have turned to the black respectively. The previous year's goodwill has recorded an impairment loss of 145.8 billion yen. The company has organized seminars for investors on 11/4, and has come up with a policy to build a new source of revenue for IT services for the office. For their mid-term plan up to FY2023/3, net sales is targeted at 2.3 trillion yen and operating income is targeted at 185 billion yen. Recommend to buy at ¥1131, target price ¥1170, cut loss if drop below ¥1105.

China Maple Leaf Education Limited (1317.HK) - Satisfactory growth on student enrollment, but still with policy risks

Investment Summary

China Maple Leaf Education Systems Limited is a leading international school operator, from preschool to grade 12 education (K-12) in China. Although the valuation lifted recently thanks to the rumor of a looser regulation on “Education Promotion Law”, we believe that even if there are any difference in regulations compared with "Draft for deliberation ", the main content will not change much. Therefore, the business risk on compulsory education and kindergarten are still very high. As a result, we downgrade the rating from “Neutral” to “Reduce”, with a TP of HK$ 3.78, 10.8% potential downside. (Closing price at 25 April 2019)

Business Update

The group announced that as of March 31, 2019, the number of students enrollment was 41,380, an increase of 38.0% over the same period last year and an increase of 13.2% from October 15, 2018. During the period, the Group acquired a 66% equity interest in a primary and secondary school in Luzhou, Sichuan Province on December 10, 2018 at a consideration of RMB 185 million. The consideration will be paid in cash and allotment and issuance of new shares of the Group to the Vendor. Subsequently, on December 27, 2018, the Group increased its shareholding of 9% by RMB 25.2 million, which lifted the total equity interest held by the company to 75%. The school enrollment was about 3,200 and the school can accommodate a total of 3,500 students. The annual tuition fee ranges from RMB 20,000 to RMB 25,000. In 2018, 4 out of 5 highest scoring students of Luzhou municipal middle school exam were from this school, implying the quality of school education.

Policy risks

It is reported that “Education Promotion Law” will be legislated this year. We believe that even if there are any difference in regulations compared with "Draft for deliberation ", the main content will not change much. For example, there will a non-profit and For-profit classification for private schools, non-profit schools will receive the same benefits as public schools, compulsory education does not allow to choose for-profit and private education should be a supplement to public education.

From a practical point of view, if the non-profit and for-profit classification needs to be implemented literally, the first thing the government needs to resolve is the problem that the compulsory education school will be profitable in the name of non-profit. If the compulsory education school still allows to make use of the legal loopholes to distribute dividends to shareholders, and at the same time continue to enjoy the benefits as a non-profit school, higher education schools may adopt the same method to its maintain non-profit status and will have lower incentives to shift to for-profit status, making the classification failed to perform.

In addition, if there are still legal loopholes in the industry that allow schools to make profits in the name of non-profits, it will certainly lead to a unfair competition to higher education schools that have been shifted into for-profits, and they may therefore protest.

Therefore, we see that the probability of the policy to be implemented literally is very high, business risks on the compulsory education and kindergarten of the Group shall be very large, and even need to spin off to the corporate structure.

Valuation

Although the valuation lifted recently thanks to the rumor of a looser regulation on “Education Promotion Law”, we believe that even if there are any difference in regulations compared with "Draft for deliberation ", the main content will not change much. Therefore, the business risk on compulsory education and kindergarten are still very high. It is very likely that the business will not be able to pay dividends to shareholders in the future. However, since it is generally believed that there will be five-year grace period, we assume that compulsory education and kindergarten business spin off five year later. We maintain 4x P/E ratio for the business to reflect its value before divestiture.

Owing to the satisfactory growth in school enrollment, we increased the CAGR on adjusted net profit in 2019-21F to 19%, with 0.9x PEG, reflecting the increase in the effective tax rate and the payment of land transfer fees after the high school segment turning into for-profit.

We derive a TP of HK$3.78, 11.8% higher than the previous TP to reflect the satisfactory growth in school enrollment. However, as the stock price goes up recently, we downgraded the rating from “Neutral” to “Reduce”, with a potential downside of 10.8%. (CNY/HKD = 0.8656)

Risk

1. VIE structure prohibited in China

2. The grace period of policies is shorter than expected

3. New acquired schools were not able to add value

Financials

Click Here for PDF format...

Recommendation on 30-4-2019
Recommendation	Reduce
Price on Recommendation Date	$ 4.240
Suggested purchase price	N/A
Target Price	$ 3.780

Writer Info

Terry Li
(Research Analyst)

Tel: +852 2277 6527

Email:
terryli@phillip.com.hk

Enquiry : 2277 6666 OR investornotes@phillip.com.hk
If you cannot read this e-mail in the proper format, please click here to view the web version.

Information contained herein is based on sources that Phillip Securities (Hong Kong) Limited and/or its affiliates ( the “Group”) believe to be accurate. The Group does not bear responsibility for any loss occasioned by reliance placed upon the contents hereof. The Group (or its employees) may have interests in relevant investment products. For details of different products’ risks, please view the Risk Disclosures Statement on http://www.phillip.com.hk.

If you DO NOT wish to receive further marketing emails from us, please click HERE to opt-out.